Form 4: Versant Exits LAVA Therapeutics with Full Share Sale

Versant Venture Capital VI and affiliated entities have fully divested their holdings in LAVA Therapeutics NV, selling over 2.9 million shares at a weighted average price of $1.4014.

Summary

• Versant Venture Capital VI, L.P. and related entities, previously a Director and 10% Owner of LAVA Therapeutics NV (LVTX), reported a complete divestment of their beneficial ownership.
• On September 19, 2025, Versant sold a total of 2,903,403 shares of LAVA Therapeutics NV common stock.
• The shares were sold at a weighted average price of $1.4014 per share, with individual transaction prices ranging from $1.40 to $1.49.
• Following these transactions, Versant Venture Capital VI, L.P. and its affiliated entities no longer beneficially own any shares of LAVA Therapeutics NV.
• The sale included 2,370,533 shares held directly by Versant Venture Capital VI, L.P. and 532,870 shares held indirectly by Versant Vantage I, L.P.

Sentiment

Score: 2

Explanation: The complete divestment by a significant institutional investor and director is a strong negative signal, indicating a potential lack of confidence in the company's future prospects.

Negatives

• A significant institutional investor and 10% owner, Versant Venture Capital VI, L.P., has completely divested its entire stake in LAVA Therapeutics NV.
• The full exit by a major investor and director could signal a lack of confidence in the company's future prospects or strategic direction.

Future Outlook

This filing does not contain any forward-looking statements or guidance from LAVA Therapeutics NV.

Industry Context

The complete divestment by a venture capital firm, especially one that was a 10% owner and director, is a notable event in the biotech sector. Such exits can sometimes precede or coincide with significant shifts in a company's strategic focus, financial health, or market perception, particularly for smaller, development-stage companies like LAVA Therapeutics NV.

Stakeholder Impact

• Shareholders: Likely negative impact due to potential downward pressure on share price and loss of confidence following a major institutional investor's complete exit.
• Company: Loss of a significant institutional shareholder and potentially a board member (if the director role was tied to the ownership), which could affect strategic guidance and future capital access.

Key Dates

Recommendation

The complete divestment by a significant institutional investor and director, Versant Venture Capital VI, L.P., signals a profound lack of confidence in LAVA Therapeutics NV's future. Such a full exit by a knowledgeable insider, especially one with board representation, typically precedes further negative developments or reflects a pessimistic outlook on the company's long-term viability or growth prospects. Investors should consider this a strong bearish indicator and evaluate exiting their positions.

Keywords

LAVA Therapeutics, LVTX, Versant Venture Capital, Insider Transaction, Form 4, Stock Sale, Beneficial Ownership, Institutional Investor Exit